Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1442-200X.2010.03034.x | DOI Listing |
Cardiovasc Pathol
November 2024
Department of Precision and Regenerative Medicine and Jonian Area, Pathology Unit, University of Bari, Bari, Italy.
Semin Neurol
February 2025
Department of Neurology, Virginia Commonwealth University, Richmond, Virginia.
Z Rheumatol
September 2024
Institut für Neuropathologie, Charité - Universitätsmedizin, Berlin, Deutschland.
Rheumatology (Oxford)
September 2024
Department of Pediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK.
Cureus
April 2024
Department of Ophthalmology, Hospital Ampang, Selangor, MYS.
Antinuclear cytoplasmic antibody (ANCA)-related scleritis is a potentially sight-threatening inflammatory condition that may occur as a primary vasculitis disorder or as a secondary vasculitis in a variety of inflammatory conditions. While ANCA has been classically associated with primary vasculitis diseases such as granulomatosis with polyangiitis (GPA), microscopic polyarteritis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA), it is interesting that in cases of lupus spectrum disease (LSD), both ANCA and atypical p-ANCA have been observed as secondary autoantibodies. Scleritis is a rare ocular manifestation of lupus disease with an incidence of around 1%.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!